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Abstract
OBJECTIVES: To evaluate the results of aortic valve replacement through sternotomic approach in redo scenarios (RAVR) vs transapical
transcatheter aortic valve replacement (TAVR), in patients in the eighth decade of life or older already undergone previous coronary artery
bypass grafting (CABG).
METHODS: One hundred and twenty-six patients undergoing RAVR were compared with 113 patients undergoing TaTAVR in terms of 30-
day mortality and Valve Academic Research Consortium-2 outcomes. The two groups were also analysed after propensity-matching.
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RESULTS: TaTAVR patients demonstrated a higher incidence of 30-day mortality (P = 0.03), stroke (P = 0.04), major bleeding (P = 0.03),
worse ‘early safety’ (P = 0.04) and lower permanent pacemaker implantation (P = 0.03). TaTAVR had higher follow-up hazard in all-cause
mortality [hazard ratio (HR) 3.15, 95% confidence interval (CI) 1.28–6.62; P < 0.01] and cardiovascular mortality (HR 1.66, 95% CI 1.02–4.88;
P = 0.04). Propensity-matched patients showed comparable 30-day outcome in terms of survival, major morbidity and early safety, with
only a lower incidence of transfusions after TaTAVR (10.7% vs RAVR: 57.1%; P < 0.01). A trend towards lower Acute Kidney Injury Network
Classification 2/3 (3.6% vs RAVR 21.4%; P = 0.05) and towards a lower freedom from all-cause mortality at follow-up (TaTAVR: 44.3 ± 21.3%
vs RAVR: 86.6 ± 9.3%; P = .08) was demonstrated after TaTAVR, although cardiovascular mortality was comparable (TaTAVR: 86.5 ± 9.7% vs
RAVR: 95.2 ± 4.6%; P = 0.52). Follow-up freedom from stroke, acute heart failure, reintervention on AVR and thrombo-embolisms were
comparable (P = NS). EuroSCORE II (P = 0.02), perioperative stroke (P = 0.01) and length of hospitalization (P = 0.02) were the determinants
of all-cause mortality at follow-up, whereas perioperative stroke (P = 0.03) and length of hospitalization (P = 0.04) impacted cardiovascular
mortality at follow-up.
CONCLUSIONS: Reported differences in mortality and morbidity after TaTAVR and RAVR reflect differences in baseline risk profiles. Given
the lower trend for renal complications, patients at higher perioperative renal risk might be better served by TaTAVR.
Keywords: Aortic valve disease • Bioprosthesis malfunction • Aortic valve replacement • Transapical transcatheter aortic valve replacement •
Redo
INTRODUCTION
Several surgical scenarios considered at increased risk of hospital
mortality—such as redo surgery—have become preferential indica-
tions for transcatheter aortic valve replacement (TAVR) although
conclusive data from randomized trials and multicentre registries
proving the superiority of transcatheter approaches over conven-
tional surgery are still lacking [1–5]. In particular, previous coronary
artery bypass grafting (CABG) at the time of aortic valve replace-
ment (AVR) (RAVR) represents a surgical challenge because of the
risk of iatrogenic injury of patent grafts, and in view of the tech-
nical issues related to myocardial protection during aortic cross-
clamping [6]. Single-centre retrospective experiences evaluating
the results of TAVR in patients with prior CABG reported similar
results between peripheral TAVR and RAVR [4], or alternatively a
better outcome with transapical TAVR (TaTAVR) compared with
RAVR [3, 7]. In contrast, the PARTNER trial subanalysis of patients
with previous CABG reported the superiority of conventional
RAVR over transcatheter procedures [8]. Moreover, a recent multi-
centre Italian registry of TaTAVR reported excellent results in
several redo scenarios [5], whereas another similar multicentre
European registry demonstrated excellent early-to-mid-term
outcome after RAVR in patients with previous CABG [9, 10]. In view
of the contradictory results and the limitations of the existing
studies, the aim of this analysis was to merge data from the two
above-mentioned multicentre registries, to evaluate ‘all-comers’
elderly patients with an aortic stenosis and a history of previous
CABG with known patent grafts and scheduled for TaTAVR or
RAVR, to define the best surgical approach.
MATERIALS ANDMETHODS
Data from ITA (Italian Registry of Trans-Apical Aortic Valve
Implantation) Registry and RECORD (REdo Cardiac Operations
Research Database) Registry have been already reported elsewhere
[5, 9–12]. Briefly, the ITA is an independent prospective multicentre
registry including all consecutive TaTAVR patients treated at 20
Italian cardiac surgery centres according to the indication of the
local Heart Team since this procedure became commercially avail-
able in 2008 [3, 7]. All patients received a Sapien or Sapien XT (since
mid-2010) TAVR (Edwards Lifesciences, Irvine, CA, USA) [11]. For the
purpose of this study, all patients in the eighth decade of life or over
with a previous CABG and enrolled for a primary aortic valve pro-
cedure or for a valve-in-valve TaTAVR were included in the analysis
(no. 113 patients, Group ITA). Overall, the ITA enrolled 774 patients
during the study period, resulting in a mean number of 38 TaTAVR/
centre [12].
RECORD is an independent multicentre registry including all sur-
gical AVR performed in patients with a history of prior cardiac
surgery since 2003 at 7 European centres, where alternative TaTAVR
treatment was not available during the study period [8–10]. For the
purpose of the study, only patients contemporary to ITA (i.e. since
2008) in the eighth decade of life with previous patent CABG were
considered (no. 126, RECORD-Group). Indeed, RECORD enrolled
422 redo patients from 7 centres since 2008, resulting in a mean
number of 60 RAVR/centre during the study period [9, 10].
In both registries, preoperative risk factors were defined according
to the EuroSCORE II criteria (www.euroscore.org/euroscore_
scoring.htm). Independent investigators evaluated patient’s
outcome and adverse events in light of the Valve Academic
Research Consortium-2 (VARC-2) definitions [13]. The following vari-
ables were collected: (i) all-cause hospital mortality; (ii) cardiovascu-
lar hospital mortality; (iii) periprocedural acute myocardial infarction
(AMI); (iv) 30-day ‘disabling or non-disabling’ stroke; (v) major/life
threatening or disabling bleeding; (vi) acute kidney injury [defined as
Class 2 or 3 of acute kidney injury network (AKIN) classification] and
need for renal replacement therapy; (vii) permanent pacemaker im-
plantation; (viii) ‘early safety’, defined as the cumulative end point at
30 days of all-cause mortality, all strokes, life-threatening bleedings,
Class 2 or 3 AKIN, coronary artery obstruction requiring intervention,
major vascular complication, valve-related dysfunction requiring
repeat procedure [13]; (ix) late all-cause mortality; (x) late cardiovas-
cular mortality; (xi) late ‘disabling or non-disabling’ stroke. Moreover,
the following ‘non-VARC-2’ outcomes were considered, because of
their prognostic and/or economic impact: (i) prolonged intubation,
defined as ≥24 h mechanical ventilation and/or respiratory insuffi-
ciency with the need for reintubation, or need for non-invasive ven-
tilation ≥24 h [9]; (ii) length of hospitalization; (iii) acute heart failure
(AHF) during follow-up; (iv) reinterventions on the aortic prosthesis
during follow-up; (v) thrombo-embolisms during follow-up;
(vi) New York Heart Association (NYHA) class at last follow-up.
Hospital and follow-up outcome data were reported for the
entire population and a propensity-matched subgroup of patients.
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Continuous variables are presented as mean and standard
deviation, categorical variables as counts and percentages.
Normally distributed continuous variables were compared
using the unpaired t-test, whereas the Mann–Whitney U-test
was used for non-normally distributed variables. Categorical
variables were analysed using either the χ2 test or Fisher’s exact
test as appropriate. Long-term overall survival and cardiovascu-
lar survival in the entire population were assessed by step-wise
Cox regression analyses. A P-value of less than 0.05 was consid-
ered significant. To reduce the effect of selection bias and
potential confounding factors, all the outcome-parameters were
adjusted by propensity-matching. A propensity score model
was built using a step-wise logistic regression (probability for
step-wise entry P = 0.20, and probability for step-wise removal
P = 0.10). Numerous factors were employed as covariates:
EuroSCORE II, gender, age, preoperative NYHA class, left ven-
tricular ejection fraction, systemic hypertension, diabetes melli-
tus, chronic obstructive pulmonary disease, chronic kidney
disease, extracardiac vasculopathy, preoperative neurological
dysfunction, previous AMI, pulmonary hypertension and previ-
ous type of cardiac surgery. Fifty-six pairs of TaTAVR and RAVR
patients having the same probability score (calliper match with
three digits approximation) were selected. Balance of matching
was then assessed by statistical comparison, using standardized
differences (with a difference >0.1 treated as significant) for con-
tinuous and Fisher’s exact test for categorical variables [14].
Survival analyses were performed using the Kaplan–Meier
method with log-rank test in the propensity-matched
population. The SPSS 13.0 program performed statistical analysis
(SPSS, Inc., Chicago, IL, USA).
RESULTS
A total of 239 consecutive patients after previous CABG were en-
rolled (126–52.7% underwent RAVR, 113–47.3%, TaTAVR). The two
populations differed for baseline characteristics (Table 1). Aortic
cross-clamping time in RAVR was 74.3 ± 33.8 min, cardiopulmonary
bypass time 119.5 ± 51.9 min. Four patients (3.5%) required cardio-
pulmonary bypass during TaTAVR. Among RAVR, 16 patients
(12.7%) required also redo CABG. Seventeen patients (13.5%) in the
RAVR cohort and 3 in the TaTAVR cohort (2.7%, P < 0.01) had redo
for degenerated aortic bioprosthesis. Within the RAVR cohort, 40
patients (31.7%) underwent preoperative CT scan, 72 (57.1%) pre-
sternotomy institution of peripheral cardiopulmonary bypass, 104
(82.5%) had patent left internal mammary artery (LIMA) graft, 85
(67.5%) underwent surgical isolation of the LIMA graft, 70 (55.6%)
LIMA-graft clamping, 110 (87.3%) had patent saphenous vein graft,
112 (88.9%) received blood cardioplegia, 108 (85.7%) had
antegrade + retrograde cardioplegia, 47 (37.3%) underwent cardio-
plegia delivery into saphenous grafts. The mean number of pre-
operative patent grafts was 2.3 ± 0.8. Among the above-mentioned
technical factors, absence of pre-sternotomy institution of periph-
eral cardiopulmonary bypass (AMI without cardiopulmonary
bypass: 4/4–100% vs AMI with cardiopulmonary bypass: 0/72–0%;
P = 0.02), absence of blood cardioplegia (AMI without blood
Table 1: Baseline characteristics of the two populations
Variables RAVR (126) TaTAVR (113) P-value
Age (years) 77 (70–88) 80 (71–88) 0.01
Height (cm) 168 (152–182) 165 (150–176) 0.01
Weight (kg) 75.8 ± 13.5 69.0 ± 15.7 <0.01
Body mass index (kg/m2) 27.1 ± 4.5 26.3 ± 13.5 0.54
EuroSCORE II 8.7 (2.4–32.7) 20.1 (4.9–29.9) <0.01
Female gender 42 (33.3%) 46 (40.7%) 0.15
Critical state 1 (0.8%) 3 (2.7%) 0.27
NYHA class I 3 (2.4%) 2 (1.8%) 0.95
NYHA class II 24 (19.0%) 22 (19.5%)
NYHA class III 84 (64.7%) 73 (64.6%)
NYHA class IV 15 (11.9%) 16 (14.2%)
Systemic hypertension 90 (71.4%) 102 (90.3%) <0.01
Diabetes mellitus 59 (46.8%) 37 (32.7%) 0.02
Renal disease 30 (23.8%) 71 (62.8%) <0.01
Vasculopathy 27 (21.4%) 78 (69.0%) <0.01
Chronic obstructive pulmonary disease 29 (23.0%) 21 (18.6%) 0.25
Neurological dysfunction 24 (19.0%) 7 (6.2%) <0.01
Pervious AMI 40 (31.7%) 7 (6.2%) <0.01
Left ventricular ejection fraction >50% 78 (61.9%) 52 (46.0%) 0.03
Left ventricular ejection fraction 30–50% 44 (34.9%) 53 (46.9%)
Left ventricular ejection fraction <30% 4 (3.2%) 8 (7.1%)
Pulmonary hypertension 22 (17.5%) 63 (55.8%) <0.01
Cognitive Impairment 7 (5.6%) 15 (13.3%) 0.03
Child-Pugh A 7 (5.6%) 12 (10.6%) 0.02
Child-Pugh B 4 (3.2%) 9 (8.0%)
Child-Pugh C – 4 (3.5%)
Serum albumin <3.5 g/dl 4 (3.2%) 13 (11.5%) 0.01
Body mass index <20 kg/m2 or weight loss >5 kg/year 8 (6.3%) 12 (10.6%) 0.23
Hostile chest 4 (3.2%) 11 (9.7%) 0.04
NYHA: New York Heart Association; AMI: acute myocardial infarction; RAVR: aortic valve replacement after previous CABG; TaTAVR: transapical TAVR.
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cardioplegia: 4/4–100% vs AMI with blood cardioplegia: 0/112–0%;
P < 0.01) and absence of antegrade + retrograde cardioplegia (AMI
without retrograde addition: 4/4–100% vs AMI with retrograde add-
ition: 0/108–0%; P < 0.01) correlated with perioperative AMI at uni-
variate analysis.
Within the TA-TAVR cohort, 96 patients had a patent LIMA graft
(84.9%, P = 0.61 vs RAVR), and 94 had patent saphenous vein
grafts (83.2%, P = 0.37 vs RAVR). The mean number of preoperative
patent grafts was 2.3 ± 0.9 (P = 0.68 vs RAVR).
Hospital outcome demonstrated lower all-cause 30-day survival
and ‘early safety’ after TaTAVR, associated with dissimilar technique-
specific morbidity between the procedures (worse stroke, major/
life-threatening/disabling bleeding after TaTAVR, higher permanent
pacemaker implantation and transfusions after RAVR) (Table 2). A
higher mean transprosthetic gradient (15.1 ± 2.7 vs 9.9 ± 3.5 mmHg;
P < 0.01) and a lower residual regurgitation (none 118/126–93.8%,
mild 6/118–4.6%, moderate 2/126–1.6% vs none 59/113–52.2%,
mild: 46/113–40.7%, moderate 8/113–7.1%; P < 0.01) was found
after RAVR versus TaTAVR, respectively. Mean follow-up was longer
in RAVR [20.1 months, 95% confidence interval (CI) 0.2–58.7 vs
TaTAVR: 12.2 months, 95% CI 0.2–30.4; P < 0.01]. RAVR reported a
lower hazard in all-cause (Fig. 1A) and cardiovascular mortality
(Fig. 1B). Causes of non-cardiovascular mortality at follow-up in
TaTAVR were cancer (no. 2), hepatic insufficiency (no. 2), pneumonia
(no. 2), gastrointestinal bleeding (no. 1). Cox regression analysis
demonstrated that EuroSCORE II [hazard ratio (HR)1.09, 95% confi-
dence limits (CL) 1.08–1.19; P = 0.02], perioperative stroke (HR 22.9,
95% CL 17.3–30.4; P = 0.01) and length of hospitalization (HR 1.14,
95% CL 1.02–1.26; P = 0.02) were significant factors determining
follow-up all-cause mortality, whereas perioperative stroke (HR 5.2,
95% CL 1.6–13.2; P = 0.03) and length of hospitalization (HR 1.07,
95% CL 1.0–1.2; P = 0.04) impacted follow-up cardiovascular mortal-
ity. Freedom from stroke was higher after RAVR (98.0 ± 2.0% vs
TaTAVR: 72.8 ± 21.1%; P = 0.02), whereas freedom from AHF (RAVR:
93.1 ± 2.8% vs TaTAVR: 81.0 ± 7.1%; P = 0.10) and thrombo-embo-
lisms (RAVR: 97.0 ± 2.3% vs TaTAVR: 99.1 ± 0.9%; P = 0.90) were
similar, with a trend towards a higher freedom from reinterventions
after RAVR (98.0 ± 2.0% vs TaTAVR: 93.0 ± 5.0%; P = 0.06). NYHA class
at last follow-up was better after RAVR (Table 3).
A propensity score selected a comparable population of 56
patients (Table 4). Within the 28 RAVR patients, 5 (17.9%) required
an associated CABG. There were 2 patients (7.1%) with degenerated
bioprosthesis in RAVR as well as in TaTAVR cohorts (P = 1.0). There
were no differences between RAVR and TaTAVR in 30-day
outcome, with the exception of a higher transfusion rate and a
trend towards higher AKIN 2/3 after RAVR (Table 2). Higher mean
trans-prosthetic gradient (14.9 ± 1.9 vs 9.1 ± 2.8 mmHg; P < 0.01)
and lower residual regurgitation (none 28/28–100% vs none 14/28–
50.0%, mild: 12/28–42.9%, moderate: 2/28–7.1%; P < 0.01) were
found in RAVR versus TaTAVR, respectively. Mean follow-up was
comparable (RAVR: 19.1 ± 15.7 months vs TaTAVR: 14.1 ± 7.6
months; P = 0.13). There was a trend towards a lower freedom from
all-cause mortality (Fig. 2A) and higher NYHA class at follow-up
(Table 3) after TaTAVR although cardiovascular mortality (Fig. 2B),
freedom from AHF (RAVR: 86.1 ± 7.4% vs TaTAVR: 79.5 ± 10.2%;
P = 0.87), from stroke (RAVR: 100% vs TaTAVR: 100%), from
thrombo-embolisms (RAVR: 100% vs TaTAVR: 96.4 ± 3.5%; P = 0.33)
and from reinterventions (RAVR: 100% vs TaTAVR: 95.8 ± 4.1%;
P = 0.41) were comparable.
DISCUSSION
The last 5 years have been characterized by the worldwide spread of
TAVR practice, progressed well beyond the initial indications limited
to patients at prohibitive or very high surgical risk [1], with a strong at-
titude to use TAVR in patients after previous cardiac surgery [15]. To
date, reports on RAVR and TAVR in redo scenarios have reached
contradictory conclusions, mostly related to the retrospective single-
centre study design, the excessive case-mix (especially in terms
of transcatheter approaches) and the baseline risk-profile of the
cohorts analysed [3, 4, 7, 8]. The present study reports the results of a
concurrent multicentre population of ‘all-comers’ with aortic valve
stenosis after previous CABG, treated with either traditional RAVR or
TaTAVR. The first finding of the study confirms previous literature
results [3, 7] that patients undergoing TaTAVR maintain a higher pre-
operative risk-profile. Therefore and as expected, these patients
achieve worse 30-day all-cause mortality, stroke, bleeding and
Table 2: Hospital and 30-day outcome in the entire population and the propensity-matched subgroups
Variables Overall population Propensity-matched cohort
RAVR (126) TaTAVR (113) P-value RAVR (28) TaTAVR (28) P-value
30-day mortality 2 (1.6%) 8 (7.1%) 0.03 – 1 (3.6%) 1.0
30-day CV mortality 2 (1.6%) 5 (4.4%) 0.18 – 1 (3.6%) 1.0
Stroke 1 (0.8%) 6 (5.3%) 0.04 – 2 (7.1%) 0.49
MLD bleeding 4 (3.2%) 11 (9.7%) 0.03 1 (3.6%) 1 (3.6%) 1.0
AMI 4 (3.2%) 1 (0.9%) 0.22 1 (3.6%) – 1.0
Prolonged intubation 14 (11.1%) 6 (5.3%) 0.08 4 (14.3%) 1 (3.6%) 0.35
AKIN 2/3 19 (15.1%) 9 (8.0%) 0.06 6 (21.4%) 1 (3.6%) 0.05
Need for dialysis 7 (5.6%) 5 (4.4%) 0.46 4 (14.3%) 1 (3.6%) 0.35
Need for pPMK 15 (11.9%) 5 (4.4%) 0.03 3 (10.7%) – 0.23
Transfusions 75 (59.5%) 23 (20.4%) <0.01 16 (57.1%) 3 (10.7%) <0.01
DSWI 2 (1.6%) – 0.89 – – –
Early safety 19 (15.1%) 28 (24.8%) 0.04 6 (21.4%) 6 (21.4%) 1.0
Hospitalization (days) 10 (5–19) 10 (4–20) 0.12 10.9 ± 6.7 8.9 ± 3.9 0.17
CV: cardiovascular; MLD: major/life threatening/disabling; AMI: acute myocardial infarction; AKIN: Acute Kidney Injury Network Classification; pPMK:
permanent pacemaker; DSWI: deep sternal wound infection; RAVR: aortic valve replacement after previous CABG; TaTAVR: transapical TAVR; TAVR:
transcatheter aortic valve replacement.
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cumulative end-point of ‘early safety’, the latter also related to the
recognized learning-curve effect [16], linked with the ITA which
encompasses all patients treated with Edwards Sapien valves since
their initial availability. Interestingly, among perioperative complica-
tions, stroke proved to play a leading role in determining unfavour-
able follow-up survival in TaTAVR-patients. This issue deserves future
investigations, also in light of the reported higher freedom from
stroke after RAVR in our experience. Another interesting information
is the extremely low incidence of major/life-threatening/disabling
bleeding after RAVR, possibly explained by the extremely low inci-
dence of iatrogenic complications at re-entry, the implemented
blood conservation strategies and anticoagulation management of
surgical patients together with an improved accuracy during haemo-
static manoeuvres in redo surgery [17]. Finally, a cumulative effect of
higher EuroSCORE II and frailty, with worse comorbidities and left
ventricular ejection fraction in TaTAVR cohort may also explain the
higher mid-term mortality and stroke rates reported in this sub-
group. In this perspective can also be interpreted the results of the
Cox regression analysis, demonstrating in both populations a critical
role on long-term survival to be played by preoperative EuroSCORE
II and prolonged hospitalization.
Figure 1: Multivariable Cox survival plotted at the mean of covariates for ‘all-
cause mortality’ (A) and cardiovascular mortality (B) in the entire population
ITA: Italian Registry of Trans-Apical Aortic Valve Implantation; CV: cardiovascu-
lar; HR: hazard ratio; CI: confidence interval; RECORD: REdo Cardiac Operations
Research Database.
Table 3: NYHA class in the entire population and in the
propensity-matched subgroups at last follow-up
NYHA I NYHA II NYHA III NYHA IV P-value
Entire population
RAVR 72 (61.0%) 38 (32.2%) 8 (6.8%) – <0.01
TaTAVR 63 (69.2%) 12 (13.2%) 9 (9.9%) 7 (7.7%)
Propensity-matched patients
RAVR 14 (53.8%) 10 (38.5%) 2 (7.7%) – 0.09
TaTAVR 14 (63.6%) 3 (13.6%) 2 (9.1%) 3 (13.6%)
NYHA: New York Heart Association; RAVR: aortic valve replacement
after previous CABG; TaTAVR: transapical TAVR; TAVR: transcatheter
aortic valve replacement.
Table 4: Baseline characteristics of the propensity-matched
sub-populations
Variables RAVR (28) TaTAVR (28) P-value
Age (years) 77.4 ± 6.8 78.8 ± 6.5 0.44
Height (cm) 166.6 ± 9.7 164.7 ± 7.6 0.43
Weight (kg) 71.9 ± 13.7 71.1 ± 15.6 0.83
Body mass index (kg/m2) 25.8 ± 3.9 26.0 ± 4.5 0.86
EuroSCORE II 16.3 ± 11.9 14.3 ± 6.5 0.45
Female gender 11 (39.3%) 7 (25.0%) 0.39
Critical state 1 (3.6%) - 1.0
NYHA class I 1 (3.6%) 1 (3.6%) 0.97
NYHA class II 4 (14.3%) 5 (17.9%)
NYHA class III 17 (60.7%) 17 (60.7%)
NYHA class IV 6 (21.4%) 5 (17.9%)
Systemic hypertension 23 (82.1%) 23 (82.1%) 1.0
Diabetes mellitus 12 (42.9%) 10 (35.7%) 0.78
Renal disease 11 (39.3%) 14 (50.0%) 0.59
Vasculopathy 17 (60.7%) 12 (42.9%) 0.28
Chronic obstructive pulmonary
disease
7 (25.0%) 7 (25.0%) 1.0
Neurological dysfunction 5 (17.9%) 2 (7.1%) 0.42
Pervious AMI 4 (14.3%) 4 (14.3%) 1.0
Left ventricular ejection fraction
>50%
15 (53.6%) 19 (67.9%) 0.26
Left ventricular ejection fraction
30–50%
13 (46.4%) 8 (28.6%)
Left ventricular ejection fraction
<30%
– 1 (3.6%)
Pulmonary hypertension 7 (25.0%) 7 (25.0%) 1.0
Cognitive impairment 4 (14.3%) 6 (21.4%) 0.36
Child-Pugh A 5 (17.9%) 6 (21.4%) 0.69
Child-Pugh B 4 (14.3%) 5 (17.9%)
Child-Pugh C – 1 (3.6%)
Serum albumin <3.5 g/dl 4 (14.3%) 4 (14.3%) 1.0
Body mass index <20 kg/m2 or
weight loss >5 kg/year
5 (17.9%) 6 (21.4%) 0.74
Hostile chest 4 (14.3%) 7 (25.0%) 0.25
NYHA: New York Heart Association; AMI: acute myocardial infarction;
RAVR: aortic valve replacement after previous CABG; CABG: coronary
artery bypass grafting; TaTAVR: transapical TAVR; TAVR: transcatheter
aortic valve replacement.
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On the other hand, a lower need for permanent pacemaker im-
plantation was documented after TaTAVR, a finding explained by the
exclusive use of Edwards Sapien transcatheter valves in this experi-
ence, with their documented low impact on the conduction system
[18], as well as by the protective effect of the rigid sewing ring of
failed bioprostheses in those patients undergoing a valve-in-valve
deployment [19]. Similarly and as previously described, a significantly
lower need for transfusions was reported after TaTAVR, directly
related to the less invasive nature of the procedure, [2–4]. Despite
this, the higher transfusion rate of RAVR cohort—confirmed also in
propensity-matched subanalysis—did not impact postoperative re-
spiratory and renal function, or survival. On the other hand, this vari-
able might impact on the hospital costs of RAVR, as recently
demonstrated by Nguyen et al. [7], a matter that certainly deserves
future revision.
The proof that the apparently better outcome of RAVR patients in
the entire population was linked to the better preoperative risk-
profile was confirmed by the results of the propensity-matched
population, showing a similar 30-day outcome with the two techni-
ques. This finding confirms those of Wilbring et al. [2] and Stortecky
et al. [4], both reporting overall equipoise in single-centre compari-
sons of RAVR and TAVR. Indeed, the only difference between the
two propensity-matched subgroups at 30 days was the higher trans-
fusion requirement, and the trend towards a higher incidence
of AKIN 2/3 after RAVR. These findings confirmed data from
Papadopoulos et al., showing a higher transfusion rate after RAVR [3].
On the other hand, the slightly worse renal effect of RAVR versus
TaTAVR is quite a new finding compared with the available literature
reporting similar renal outcome, implying a higher injurious effect
of transfusions and cardiopulmonary bypass on the one hand, com-
pared with that of contrast medium administration on the other [20].
When mid-term outcome was considered, propensity-matched
analysis demonstrated comparable results between RAVR and
TaTAVR in contrast to the overall examined population, substantiat-
ing a direct dependence from baseline risk-profile. Therefore, our
data demonstrate that in high-risk elderly patients with previous
CABG, TaTAVR and RAVR can be considered complementary tech-
niques. These data confirm the recent study by Nguyen et al.,
reporting similar risk-adjusted mid-term survival between TAVR
and RAVR in previous CABG [7]. Certainly other factors not captured
by current risk-profiles (e.g. multimorbidity interactions, disability,
frailty and cognition) may help to explain the contrast between the
trend for higher all-cause mortality and the comparable cardiovas-
cular mortality of our propensity-matched subanalysis [21, 22].
Similarly, a combination of baseline risk-profile, ‘frailty items’ and
‘cognitive functions’ can help to explain the apparent discrepancy
between the better NYHA class at follow-up in overall RAVR popu-
lation and the presence of only a trend towards a better NYHA after
RAVR in the propensity-matched population [21, 22].
Finally, when valve performance was considered, we reported
higher transprosthetic gradients after RAVR and higher residual re-
gurgitation after TaTAVR in the entire and the propensity-matched
populations. The higher residual aortic regurgitation after TaTAVR
certainly relates to the first-generation nature of TaTAVR of the
present study [23, 24] and the low prevalence of valve-in-valve
procedure of our ‘transcatheter’ cohort [25]. We cannot exclude
that these data might have impacted also NYHA class at follow-up.
Furthermore, the low prevalence of valve-in-valve procedures in
TaTAVR cohort and the stentless nature of TaTAVR, compared with
the predominant stented structure of RAVR implanted in our
population, explain the higher gradients reported after traditional
surgery [2–4, 25]. It is noteworthy that the higher gradients
reported in RAVR did not impact survival, functional class and
AHF episodes at follow-up.
The main limitation of the study is related to the retrospective
nature of the data-analysis. The second limitation is related to the
fact that the present comparison does not adhere to any of the
primary purposes according to which the two source registries have
been conceptualized. The third limitation stems from the absence
of a ‘cost-effective’ analysis between RAVR and TaTAVR in this high-
risk population. Another limitation is related to the fact that the
contemporary availability of RAVR in the 20 ITA-contributor centres
might have led to a ‘selection bias’ of sicker patients towards
TaTAVR, regardless of the similar risk factors captured by the
EuroSCORE II, and thus potentially unmatchable despite propensity
analysis. Nevertheless, some other VARC-2 risk factors not captured
by EuroSCORE II (e.g. hepatic function, cognition and nutritional
Figure 2: Freedom from ‘all-cause mortality’ (A) and cardiovascular mortality
(B) in the propensity-matched population. ITA: Italian Registry of Trans-Apical
Aortic Valve Implantation; CV: cardiovascular; RAVR: aortic valve replacement
after previous CABG; TaTAVR: transapical TAVR; RECORD: REdo Cardiac
Operations Research Database.
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status) have been analysed, according to which TaTAVR patients
still reported a higher baseline risk-profile compared with RAVR
patients, thus requiring propensity-matching for an acceptable
comparison. The last limitation is related to the restricted number
of propensity-matched patients selected in the study, associated to
the employed propensity analysis, which considered quite several
factors as covariates potentially influencing treatment-group
allocation.
However, the above-mentioned limitations stem from the
observational nature of the two registries, which on the opposite
represent a ‘real world’ picture of concurrent RAVR and TaTAVR in
‘all-comers’ to redo procedures after CABG at different European
institutions. Moreover, the main strengths are related to the multi-
centre nature and the contemporaneity of the two registries.
Finally, this is the only study besides that of Nguyen et al. [7] com-
paring TaTAVR and RAVR complying with VARC-2 definitions of
end-points.
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